全部照片(1)
About This Item
經驗公式（希爾表示法）:
C4H12NaNO7P2 · 3 H2O
CAS號碼:
分子量：:
325.12
MDL號碼:
分類程式碼代碼:
41106300
PubChem物質ID:
NACRES:
NA.77
推薦產品
化驗
≥97% (NMR)
形狀
powder
顏色
white
溶解度
water, double-distilled: 10 mg/mL
儲存溫度
−20°C
SMILES 字串
[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O
InChI
1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1
InChI 密鑰
DCSBSVSZJRSITC-UHFFFAOYSA-M
基因資訊
human ... FDPS(2224)
尋找類似的產品？ 前往 產品比較指南
應用
阿仑膦酸钠三水合物已被用于：钛植入物的磷酸钙纳米颗粒（nCaP）二膦酸盐（BP）涂层并用于分析其成骨能力 从老年骨质疏松症患者和健康人群中分离的人骨髓基质细胞（hBMSC）的成骨分化 处理成骨细胞祖细胞和成骨细胞并通过传统测定和简单的数字图象分析研究其对成骨细胞行为的影响
生化／生理作用
阿仑膦酸钠三水合物是一种骨吸收抑制剂；法尼基二磷酸合成酶抑制剂 (IC 50 = 460 nM)；CD45 蛋白酪氨酸磷酸酶抑制剂。
阿伦膦酸盐是一种含氮二膦酸盐，可阻断甲羟戊酸途径 并限制破骨功能和活性。阿仑膦酸钠三水合物是一种骨吸收抑制剂、法尼基二磷酸合成酶抑制剂和 CD45 蛋白酪氨酸磷酸酶抑制剂。
儲存和穩定性
重溶后，建议在-20°C下分装冻存。储备液在-20°C条件下可稳定保存6个月。
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
客戶也查看了
Robert Josse et al.
Current medical research and opinion, 29(3), 205-216 (2013-01-10)
According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone
Mattias Ulmner et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(1), 76-82 (2013-09-03)
To estimate the incidence of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) associated with the use of oral BPs and osteonecrosis of the jaw (ONJ) not associated with current or previous medication with a BP or radiotherapy to the head
Shmuel Banai et al.
American heart journal, 165(2), 234-240 (2013-01-29)
Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose
Xuefeng Hu et al.
Tissue engineering. Part A, 19(17-18), 1919-1930 (2013-04-02)
Fibrous encapsulation can impair implant osseointegration and cause implant failure but currently there are limited strategies to address this problem. Since bisphosphonates (BPs), a class of drugs widely used to treat bone diseases, was recently found to induce fibroblast apoptosis
Wei-Yih Chiu et al.
The Journal of clinical endocrinology and metabolism, 98(4), E723-E726 (2013-03-09)
Bisphosphonates effectively increase bone mineral density and reduce fracture risk in patients with osteoporosis, but there are concerns about osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) in the long-term users. So far both complications have not been
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務